Pfizer Inc. and partner BioNTech SE have submitted data to U.S. health regulators needed to clear a Covid-19 booster shot among the general public.

The companies said Monday they sent to the U.S. Food and Drug Administration results from a small, early-stage study showing a third dose of their vaccine generated higher levels of neutralizing antibodies against the original virus and against the Beta and Delta variants than the standard two-dose regimen.

The addition of the third dose also appeared safe in the trial, the companies said.

Given the immune response boost from a third dose, the companies said, a booster shot within six months to a year after the second shot might help maintain protection against symptomatic Covid-19.

Pfizer and BioNTech are also conducting a larger late-stage study evaluating whether a third dose safely provides more protection. The companies said they expect those results shortly and will then submit the data to the FDA.

This post first appeared on wsj.com

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

How Companies Raise Prices Without Raising Prices

The demand curve imposes its tyranny on every business. Raise prices and…

U.S. Railroad Strike Averted as Tentative Deal Is Reached, Biden Says

WASHINGTON—The White House said Thursday it had reached a tentative agreement to…

Home prices cooled at a record pace in June, according to housing data firm

Rising mortgage rates and inflation in the wider economy caused housing demand…

Snapchat makes it harder for kids to buy drugs

Snapchat’s parent company announced Tuesday that it was taking more steps to…